Natural and synthetic bacteriophage-based therapies
Also Clin0 NCFB infection; AP-SA02 Clin1b/Clin2a S. aureus bacteremia, Clin0 PJI; AP-PA03 Clin0 pneumonia; 2 undisclosed programs RD infections
Armata Pharmaceuticals is creating bacteriophage therapeutics to meet the global challenge of antibiotic resistance. Antibiotic resistance is increasing making it harder to treat common infections creating a major threat to public health. As an alternative, Armata is harnessing the power of natural and synthetic phages that infect and rapidly kill bacteria. The advantage of this approach over traditional antibacterial therapies is that the typical life cycle of a lytic phage only stops once the pathogenic bacteria have been eliminated. Moreover, phage activity is independent of antibiotic resistance and they are highly specific to a bacterial host, circumventing microbiome damage. Armata’s lead phage programs are against Pseudomonas aeruginosa for cystic fibrosis and Staphylococcus aureus.